SOTIO's SOT106 Gains FDA Orphan Drug and Fast Track Designations in Soft Tissue Sarcoma and Osteosarcoma
核心洞察
The FDA granted SOT106 Orphan Drug Designation for soft tissue sarcoma (搜索) and Fast Track Designation for osteosarcoma (搜索), adding to earlier designations in both indications.
SOT106 is an antibody-drug conjugate targeting LRRC15 (搜索), a clinically validated target broadly expressed across multiple highly prevalent sarcoma subtypes.
Preclinical patient-derived xenograft models of osteosarcoma (搜索) and soft tissue sarcoma (搜索) showed SOT106 was potent and well tolerated with a high therapeutic index.
SOTIO Biotech (搜索) announced that the U.S. Food and Drug Administration has granted SOT106 Orphan Drug Designation for the treatment of soft tissue sarcoma (搜索) (STS) and Fast Track Designation for the treatment of osteosarcoma (搜索). The designations support the company's planned clinical development of the investigational antibody-drug conjugate (ADC) across multiple sarcoma subtypes.
With these additions, SOT106 has now received both Orphan Drug and Fast Track Designations for osteosarcoma (搜索) and STS, according to the Prague-, Basel- and Boston-based company, which is owned by PPF Group (搜索).
LRRC15 as the Program's Foundation
SOT106's potential across these indications is rooted in selective binding to leucine-rich repeat-containing 15 (LRRC15 (搜索)), described by SOTIO as a clinically validated target broadly expressed across multiple highly prevalent sarcoma subtypes.
The construct combines SOTIO's proprietary LRRC15 (搜索)-targeting antibody with LigaChem Biosciences (搜索)' ConjuAll site-specific conjugation and a beta-glucuronidase-cleavable linker. The linker is designed to remain stable in circulation and release the payload selectively within the tumor.
Preclinical data, including patient-derived xenograft models of both osteosarcoma (搜索) and STS, indicate that SOT106 is potent and well tolerated, with a high therapeutic index and strong anti-tumor activity.
Regulatory Incentives and Development Timeline
Fast Track Designation and Orphan Drug Designation are intended to support the development of promising therapies for rare diseases and areas of high unmet need, providing opportunities for enhanced regulatory engagement and other incentives that may help accelerated development.
SOTIO expects to initiate a first-in-human clinical trial of SOT106 later this year, with the study on track to be initiated in 2026.
"These additional designations mark another important milestone for SOT106 and reflect the growing momentum behind our ADC portfolio," said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. "Patients with sarcoma continue to face limited treatment options, underscoring the need for innovative targeted therapies. As we advance SOT106 toward the clinic, we believe it has the potential to become an important treatment option for patients in need."
Broader ADC and Immunocytokine Pipeline
SOTIO is a clinical-stage biopharmaceutical company advancing a focused pipeline of next-generation ADCs for solid tumors, pursuing targeted therapies for cancers with significant unmet need and broad expansion potential.
Its two lead ADC programs, SOT106 and SOT109, are described as potential best-in-class therapies designed to rapidly advance to clinical proof of concept. SOT109 is currently in a Phase 1/2 study for colorectal cancer (搜索) and has received Fast Track Designation from the FDA. SOT106, targeting LRRC15 (搜索) for sarcoma and other solid tumors, now holds both Orphan Drug Designation and Fast Track Designation.
The broader pipeline includes SOT201, a next-generation PD-1 (搜索)-targeting immunocytokine, currently being evaluated in the Phase 1 VICTORIA-01 study in patients with solid tumors.